CYP19A1 (aromatase) is a cytochrome P450 monooxygenase that catalyzes the conversion of C19 androgens (androstenedione and testosterone) to C18 estrogens (estrone and estradiol), respectively 12. The enzyme performs three successive oxidations of androgens: two conventional oxidations at C19 yielding hydroxylated and aldehyde intermediates, followed by aromatization involving C1-beta hydrogen abstraction and C10-C19 bond cleavage to produce a phenolic A ring 3. CYP19A1 also converts dihydrotestosterone to delta1,10-dehydro 19-nordihydrotestosterone and displays 2-hydroxylase activity toward estrone 4. The enzyme operates through a mechanism inserting molecular oxygen into substrates while reducing the second oxygen atom to water, with reducing equivalents supplied by NADPH via cytochrome P450 reductase 3. In clinical contexts, CYP19A1 polymorphisms (rs10046) show a trend toward association with endometriosis risk 5, while CYP19A1 expression in granulosa cells correlates with follicular estradiol levels in non-affected women but not in endometriosis patients 6. Additionally, CYP19A1 variants (R264C and R264H) demonstrate altered aromatase activity depending on cytochrome P450 oxidoreductase co-expression patterns 7, and external factors like bisphenol A can inhibit CYP19A1 protein levels, reducing estradiol production 8.